The SF fragment screen also identified novel hits for BCL6, a therapeutictarget under investigation for conditions such as blood, breast, andlung cancers.42 Interestingly, the screenafforded two hit series that were found to covalently modify residueson opposite sides of the same pocket, one to a tyrosine and one toa histidine, highlighting the versatility of the approach in targetingnucleophilic amino acid residues within a binding pocket. The gene discussed is BCL6; the disease is cancer.